Technical Trend Overview and Price Movement
As of 12 Feb 2026, Strides Pharma’s stock price closed at ₹875.30, down 1.01% from the previous close of ₹884.20. The intraday range saw a high of ₹899.00 and a low of ₹870.35, reflecting some volatility but limited directional conviction. The stock remains well below its 52-week high of ₹1,024.90, yet comfortably above its 52-week low of ₹551.00, indicating a broad trading range over the past year.
The technical trend has shifted from mildly bullish to sideways, signalling a pause or consolidation phase after recent upward momentum. This is corroborated by the daily moving averages, which remain mildly bullish, suggesting that while short-term momentum is intact, the stock is encountering resistance that may limit further gains without a catalyst.
MACD and Momentum Oscillators Signal Caution
The Moving Average Convergence Divergence (MACD) indicator presents a mildly bearish outlook on both weekly and monthly timeframes. This suggests that the momentum that propelled the stock higher in recent months is waning, with the MACD line potentially crossing below the signal line or remaining below it, a classic sign of weakening buying pressure.
Complementing this, the Know Sure Thing (KST) oscillator also shows mildly bearish signals on weekly and monthly charts, reinforcing the view that momentum is decelerating. The absence of a strong bullish crossover in these oscillators indicates that investors should exercise caution, as the risk of a pullback or sideways consolidation has increased.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
RSI and Bollinger Bands: Mixed Signals
The Relative Strength Index (RSI) on the weekly chart currently shows no definitive signal, hovering in a neutral zone that neither indicates overbought nor oversold conditions. However, the monthly RSI is bearish, suggesting that on a longer-term basis, the stock may be losing upward momentum and could be vulnerable to further downside or consolidation.
Bollinger Bands provide a contrasting view: weekly readings are mildly bearish, indicating the stock price is closer to the lower band and may be under selling pressure in the short term. Conversely, the monthly Bollinger Bands are mildly bullish, implying that over a longer horizon, volatility remains contained and the stock could find support near current levels.
Moving Averages and Volume Trends
Daily moving averages remain mildly bullish, with short-term averages likely positioned above longer-term averages, signalling that the stock has maintained some upward momentum despite recent weakness. However, the lack of a strong breakout above recent highs suggests that the stock is consolidating rather than trending decisively higher.
On the volume front, the On-Balance Volume (OBV) indicator shows no clear trend on both weekly and monthly charts, indicating that volume is not confirming price moves. This lack of volume confirmation often precedes sideways price action or a potential reversal, underscoring the need for investors to monitor volume spikes for clues on future direction.
Dow Theory and Broader Market Context
According to Dow Theory, the weekly trend remains mildly bullish, which aligns with the daily moving averages and suggests that the broader intermediate trend is still positive. However, the monthly Dow Theory reading shows no clear trend, reflecting uncertainty in the longer-term outlook.
Comparing Strides Pharma’s returns with the Sensex reveals a mixed performance. Over the past week, Strides outperformed the Sensex with a 0.75% gain versus 0.50%. However, over the last month, the stock declined by 7.18% while the Sensex rose 0.79%. Year-to-date, Strides is down 3.00% compared to the Sensex’s 1.16% decline. On a longer horizon, the stock has significantly outperformed, delivering a 26.91% return over one year versus the Sensex’s 10.41%, and an impressive 510.11% over three years compared to the Sensex’s 38.81%.
Valuation and Market Capitalisation Insights
Strides Pharma holds a Mojo Score of 56.0 with a Mojo Grade upgraded to Hold from Sell as of 9 Feb 2026, reflecting improved sentiment based on recent technical and fundamental assessments. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation within its sector. This upgrade signals that while the stock is not yet a strong buy, it has moved out of the sell territory, suggesting stabilisation and potential for selective accumulation.
Strides Pharma Science Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway and Outlook
Strides Pharma Science Ltd currently exhibits a complex technical profile with mixed signals across key indicators. The mildly bearish MACD and KST on weekly and monthly charts caution investors about waning momentum, while the mildly bullish daily moving averages and weekly Dow Theory readings suggest underlying strength remains. The sideways trend indicates a consolidation phase, where the stock may trade within a range before a decisive move.
Investors should watch for a sustained breakout above recent highs near ₹900 to confirm a resumption of bullish momentum. Conversely, a breakdown below support levels near ₹870 could signal further downside risk. The neutral weekly RSI and lack of volume confirmation via OBV reinforce the need for vigilance and selective positioning.
Given the stock’s strong long-term outperformance relative to the Sensex and recent upgrade to a Hold rating, Strides Pharma remains a stock of interest for investors with a medium to long-term horizon. However, the current technical signals advise caution and suggest that new entrants consider waiting for clearer confirmation before committing fresh capital.
Summary of Technical Ratings
• MACD: Weekly and Monthly - Mildly Bearish
• RSI: Weekly - Neutral, Monthly - Bearish
• Bollinger Bands: Weekly - Mildly Bearish, Monthly - Mildly Bullish
• Moving Averages: Daily - Mildly Bullish
• KST: Weekly and Monthly - Mildly Bearish
• Dow Theory: Weekly - Mildly Bullish, Monthly - No Trend
• OBV: Weekly and Monthly - No Trend
Overall, the technical landscape suggests a cautious Hold stance, consistent with the recent Mojo Grade upgrade, with investors advised to monitor momentum indicators closely for signs of trend confirmation or reversal.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
